MedPath

Immatics Biotechnologies GmbH

Immatics Biotechnologies GmbH logo
🇩🇪Germany
Ownership
Public, Subsidiary
Established
2000-01-01
Employees
101
Market Cap
-
Website
http://www.immatics.com

Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape

• DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies. • Key drug candidates include XL092 (Exelixis), Adagrasib (Mirati Therapeutics), Olaparib (Merck/AstraZeneca), and novel approaches like LYL845, an autologous tumor-infiltrating lymphocyte therapy from Lyell Immunopharma. • The metastatic colorectal cancer segment shows particular promise with 150+ companies advancing 180+ pipeline therapies, including innovative treatments targeting specific mutations and immune pathways.
© Copyright 2025. All Rights Reserved by MedPath